Business
Issue and Allotment of Ordinary Shares
Issue and Allotment of Ordinary Shares.
About this update from Iconic Labs Plc
[{"type":"text","content":"\n \nRNS Number : 5209G WideCells Group PLC 06 November 2018 \n\n6 November 2018\nWideCells Group PLC ('WideCells Group' or 'the Group')\nIssue and Allotment of Ordinary Shares following Exercise of Conversion Rights\n \nWideCells Group PLC, the healthcare services group focussed on providing stem cell services and ground-breaking insurance for stem cell treatment, announces that following the financing agreement entered into by the Group and the European High Growth Opportunities Securitization Fund ('Investor') (see RNS dated 27 September 2018), pursuant to which the Group issued bonds ('Convertible Bonds') convertible into ordinary shares of £0.0025 each in the Group ('Ordinary Shares') to the Investor, the Group has now received a third notice of exercise from the Investor in respect of the exercise by the Investor of its conversion rights under the Convertible Bonds in the principal amount of £25,000.00, resulting in the issue to the Investor of 10,000,000 new Ordinary Shares ('Conversion Shares').\n \nThe Group has agreed, subject only to Admission (as defined below), to issue the Conversion Shares and accordingly application will be made for the Conversion Shares to be listed on the Standard segment of the Official List of the UK Listing Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc ('Admission').\n \nAdmission is expected to take place on 12 November 2018. The Conversion Shares will rank pari passu in all respects with all existing Ordinary Shares.\n \nFollowing Admission of the Conversion Shares, the Group's enlarged issued share capital will comprise 151,352,698 Ordinary Shares with voting rights. The Group does not hold any shares in treasury. The figure of 151,352,698 Ordinary Shares may be used by shareholders in the Group as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Group under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.\n \n**ENDS**\n \nFor further information, please visit the Company's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:\n \n\n\n\nWideCells Group\n\n\nCEO - João Andrade\n\n\nTel: +351 919 033 171\n\n...